KRYS Krystal Biotech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRYS

Price (delayed)

$307.43

Market cap

$9.06B

P/E Ratio

39.67

Dividend/share

N/A

EPS

$7.75

Enterprise value

$8.57B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 98

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Highlights
The net income has soared by 82% YoY and by 10% from the previous quarter
The EPS has soared by 79% YoY and by 9% from the previous quarter
KRYS's price to earnings (P/E) is 29% higher than its last 4 quarters average of 30.2
The company's quick ratio fell by 5% QoQ and by 2.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.krystalbio.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KRYS

KRYS stock price

How has the Krystal Biotech stock price performed over time
Intraday
1.86%
1 week
-0.92%
1 month
7.14%
1 year
132.85%
YTD
24.7%
QTD
19.01%

Financial performance

How have Krystal Biotech's revenue and profit performed over time
Revenue
$417.3M
Gross profit
$392.96M
Operating income
$178.64M
Net income
$225.03M
Gross margin
94.2%
Net margin
53.9%
The net income has soared by 82% YoY and by 10% from the previous quarter
The operating income has soared by 64% YoY and by 11% from the previous quarter
The net margin has grown by 45% YoY and by 2.5% from the previous quarter
The operating margin has grown by 31% YoY and by 3.1% from the previous quarter

Price vs fundamentals

How does KRYS's price correlate with its fundamentals

Growth

What is Krystal Biotech's growth rate over time

Valuation

What is Krystal Biotech stock price valuation
KRYS P/E details
P/E
39.67
P/B
7.04
P/S
21.58
EV/EBIT
41.34
EV/EBITDA
40.06
EV/Sales
20.54
The EPS has soared by 79% YoY and by 9% from the previous quarter
KRYS's price to earnings (P/E) is 29% higher than its last 4 quarters average of 30.2
KRYS's P/B is 57% above its 5-year quarterly average of 4.4 and 38% above its last 4 quarters average of 5.0
Krystal Biotech's equity has increased by 30% YoY and by 4.7% QoQ
The P/S is 38% above the last 4 quarters average of 15.3
The revenue has grown by 25% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Krystal Biotech business performance
Krystal Biotech's ROA has increased by 43% YoY and by 2.9% from the previous quarter
The ROE has grown by 42% YoY and by 3.2% from the previous quarter
The ROS has grown by 20% YoY and by 2.1% from the previous quarter
Krystal Biotech's return on invested capital has increased by 17% YoY and by 6% QoQ

Dividends

What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRYS.

Financial health

How did Krystal Biotech financials performed over time
The total liabilities has grown by 34% YoY and by 5% from the previous quarter
The company's total assets rose by 30% YoY and by 4.7% QoQ
The debt is 99% less than the equity
Krystal Biotech's equity has increased by 30% YoY and by 4.7% QoQ
The debt has contracted by 6% YoY and by 2.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.